Prilenia Neurotherapeutics Ltd.

The University of Texas System

Michal Geva

Michael Hayden

Ralph Laufer

Aric Orbach

Merav Bassan

Ilya Bezprozvanny

Angela Cenci Nilsson

Neta Zach

Hermann Kurt Russ

Elena Berelovich

The subject invention provides a method for treating Parkinsonism or symptoms thereof by low dose pridopidine.

Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism

The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.

Use of pridopidine for treating rett syndrome

The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia.

Pridopidine for treating drug induced dyskinesias

The subject invention provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject.

Treatment of neurodegenerative eye disease using pridopidine

This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.

Use of pridopidine to improve cognitive function and for treating Alzheimer's disease

Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.

Method of treating amyotrophic lateral sclerosis with pridopidine

The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions.

Growing community of inventors

Even-Yehuda, Israel

Michal Geva